Drugs / indibulin
indibulin
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00591383 | Jan 2008 → Jun 2013 | cancer | Alaunos Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT00591890 | Oct 2007 → Jun 2008 | — | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00591292 | Jun 2007 → Jun 2013 | cancer | Alaunos Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT00591136 | Apr 2003 → Sep 2008 | cancer | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01113970 | Mar 2010 → May 2013 | breast cancer | Alaunos Therapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT00726687 | Jun 2008 → Jun 2013 | cancer | Alaunos Therapeutics | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | indibulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00591890 ↗ |
| Known as | D-24851 | ChEMBL registry synonym — accepted as the source's own label CHEMBL49642 ↗ |
| Known as | Indibulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL49642 ↗ |
| Known as | Indibuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL49642 ↗ |
| Known as | ZIO-301 | ChEMBL registry synonym — accepted as the source's own label CHEMBL49642 ↗ |
| Action | Inhibit | “Indibulin, a synthetic inhibitor of tubulin assembly, has shown promising anticancer activity with a minimal neurotoxicity in preclinical animal studies and in Phase I clinical...” PMID 30120268 ↗ Aug 2018 |
| Modality | Small molecule | “Indibulin, a synthetic inhibitor of tubulin assembly” PMID 30120268 ↗ Aug 2018 |